Navigation Links
Apligraf Reimbursement to Benefit from New CMS Codes
Date:11/10/2010

CANTON, Mass., Nov. 10, 2010 /PRNewswire/ -- Organogenesis, Inc. announced today that Apligraf®, the only product with FDA approval for the treatment of both diabetic foot ulcers and venous leg ulcers, will have two new procedure codes assigned by the Centers for Medicare & Medicaid Services (CMS) as of January 2011. The new codes will enable physicians to receive appropriate reimbursement for each application of Apligraf in accordance with its FDA labeling criteria, which includes weekly assessment and up to 5 applications as needed.

The new Healthcare Common Procedure Coding System (HCPCS) codes will include site preparation and debridement and 0-day global billing period. The new codes are:

  • G0440 (Application of tissue cultured allogeneic skin substitute or dermal substitute; for use on lower limb, includes the site preparation and debridement if performed; first 25 sq cm or less) and;
  • G0441 (Application of tissue cultured allogeneic skin substitute or dermal substitute; for use on lower limb, includes the site preparation and debridement if performed; each additional 25 sq cm).

As part of its annual rulemaking process, CMS reviewed feedback from key stakeholders, noting that:

"…some stakeholders believe that the current coding and payment provides a financial incentive for the selection of one tissue cultured product over another, rather than facilitating clinical decision-making based solely on the most clinically appropriate product for the patient's case."

The new codes were created to address inconsistencies in valuing the use of bioengineered skin substitutes for the treatment of chronic wounds. For example, some application codes allowed for separate billing of site preparation and debridement, whereas Apligraf's application codes already included site preparation and debridement.

"Under the new codes, physicians will be reimbursed fairly for each application of Apligraf as directed by our FDA labeling, based on our pivotal clinical trials," stated Geoff MacKay, CEO of Organogenesis. "The new codes, together with a 0-day global billing period, will eliminate unequal financial incentives in the selection of products for the treatment of chronic wounds as well as help ensure that physicians make their treatment decisions based solely on clinical benefit."

Apligraf is the first bio-engineered living cell-based product to have received FDA approval for treatment of diabetic foot ulcers and venous leg ulcers. Clinical studies of Apligraf application were based on up to 5 treatments, comprising weekly assessments and/or applications, over a 12-week period. Over 350,000 Apligraf units have been shipped to date, reaching patients around the world.

About Apligraf

Apligraf contains two layers of human living cells: a layer of differentiated keratinocytes and a layer of fibroblasts in a collagen matrix. When placed on a wound previously unresponsive to treatment, Apligraf provides cells, collagen matrix and other proteins that provide a covering that has been demonstrated to promote healing. In multiple controlled clinical studies, Apligraf has been shown to be an effective and safe wound care treatment, superior to conventional treatments.

About Organogenesis, Inc.

Having pioneered the field, Massachusetts-based Organogenesis, Inc. is a leading regenerative medicine company focused in the areas of bioactive wound healing, oral tissue regeneration and bio-surgery. The company's mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. For more information, visit www.organogenesis.com.   


'/>"/>
SOURCE Organogenesis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Apligraf® Approved by Saudi Food and Drug Authority for Treatment of Chronic Wounds
2. UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth
3. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
4. Local Chinese Government Authorities Approve Pricing and Reimbursement for NeoStems Licensed Adult Stem Cell Treatments for Orthopedic Applications in China
5. Medical Technology, Funding & Government Experts Address Business, Investment, Reimbursement, Compliance, Innovation, Regulatory and Legal Issues at AdvaMed 2010
6. Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan
7. WATCHMAN® Receives German Reimbursement Coverage
8. Will MHLW Changes in Reimbursement Drive Japanese Physicians to Increase Usage of Chronic Dialysis Catheters?
9. Millennium Laboratories, Inc. Urges Medicare to Reconsider the 2010 Physician Reimbursement for Point-of-Care Urine Drug Screen Devices
10. Dr. Robert J. Rubin to Join Halt Board as Reimbursement Advisor
11. Schwarz Pharma Pays $22 Million to Settle False Claims Allegations Concerning Reimbursement for Unapproved Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its ... http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... 2016 ACME Markets, ... Delaware County Councilman Dave White ... all ACME pharmacies across Delaware ... and Prevention (CDC), naloxone has saved 26,463 lives nationwide over the ... Delaware County were authorized to administer naloxone to ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... In the midst of making plans ... most important arrangement — planning a safe way of getting home after the festivities. ... Unfortunately, these celebrations often lead to drunk drivers on the roads who become involved ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Is the part ... Mother’s Day just a few days away, it’s a good opportunity to raise awareness ... to the American Academy of Dermatology, 40% of women experience hair loss or ‘thinning’ ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... for blood and service orders. Blood suppliers and their hospitals use BloodHub ... “BloodHub serves 13,000 active users across 2,100 hospitals who use our platform to ...
(Date:5/5/2016)... Wisconsin (PRWEB) , ... May 05, 2016 , ... ... proud to announce that Dr. Julie Lombardo, PT, DPT, MA, OCS, WCS, has ... of the WPTA Private Practice Award. The WPTA Private Practice Award is awarded ...
(Date:5/4/2016)... ... May 05, 2016 , ... The talus is the part ankle ... falls, or traffic accidents can cause the talus bone to be fractured, and a ... In a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon Dr. ...
Breaking Medicine News(10 mins):